Secukinumab provides significant and sustained improvement in nail psoriasis and signs and symptoms of psoriatic arthritis in patients with nail phenotype: 52-week results from the phase III future 5 study
No Thumbnail Available
File version
Author(s)
Nash, Peter
Mease, Philip J
Kirkham, Bruce
Balsa, Alejandro
Singhal, Atul
Quebe-Fehling, Erhard
Pricop, Luminita
Gaillez, Corine
Mease, Philip J
Kirkham, Bruce
Balsa, Alejandro
Singhal, Atul
Quebe-Fehling, Erhard
Pricop, Luminita
Gaillez, Corine
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
2019
Size
File type(s)
Location
Madrid, Spain
License
Journal Title
Conference Title
Annals of the Rheumatic Diseases
Book Title
Edition
Volume
78
Issue
Suppl 2
Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
Item Access Status
Note
Access the data
Related item(s)
Subject
Clinical sciences
Immunology
Science & Technology
Life Sciences & Biomedicine
Rheumatology
Persistent link to this record
Citation
Nash, P; Mease, PJ; Kirkham, B; Balsa, A; Singhal, A; Quebe-Fehling, E; Pricop, L; Gaillez, C, Secukinumab provides significant and sustained improvement in nail psoriasis and signs and symptoms of psoriatic arthritis in patients with nail phenotype: 52-week results from the phase III future 5 study, Annals of the Rheumatic Diseases, 2019, 78 (Suppl 2), pp. 921-922